Michael Barbella, Managing Editor11.08.22
Johnson & Johnson MedTech has named Ahmet Tezel, Ph.D., as company group chairman and Global Head of MedTech Innovation and R&D, following the retirement of Peter Shen, Ph.D.
Tezel will report to Ashley McEvoy, executive vice president and Worldwide Chairman, Johnson & Johnson MedTech, and will join the MedTech global leadership team. In this role, Tezel will be responsible for end-to-end aspects of research and development for Johnson & Johnson MedTech as we make our solutions smarter, less invasive, and more personalized. Ahmet will work with Shen before he retires at the end of the year to ensure a smooth transition.
Under Tezel’s leadership as Worldwide Vice President, R&D for Ethicon, the Ethicon R&D pipeline value increased over two-fold. He also played an integral role in creating synergies between Ethicon and the Robotics and Digital Solutions teams to enhance integrations of technology platforms and utilization of product development best practices. Tezel joined Johnson & Johnson with broad experience in the medical technology industry including a strong history of driving innovation strategy, delivering new products to market as well as retaining and advancing key talent. He is a Credo-based leader who is dedicated to developing people and creating an inclusive work environment.
Tezel has held various executive positions in research, development, and tech transfer across a wide range of medical specialties and companies, including Alcon and Allergan. He earned a Ph.D. in chemical engineering from the University of California-Santa Barbara in transdermal drug delivery and vaccination, as well as a B.Sc., and M.Sc. in chemical engineering from Bogazici University in Istanbul, Turkey. Tezel and his family will continue to live in Summit, NJ.
Shen is retiring after working for Johnson & Johnson for more than 25 years.
Tezel will report to Ashley McEvoy, executive vice president and Worldwide Chairman, Johnson & Johnson MedTech, and will join the MedTech global leadership team. In this role, Tezel will be responsible for end-to-end aspects of research and development for Johnson & Johnson MedTech as we make our solutions smarter, less invasive, and more personalized. Ahmet will work with Shen before he retires at the end of the year to ensure a smooth transition.
Under Tezel’s leadership as Worldwide Vice President, R&D for Ethicon, the Ethicon R&D pipeline value increased over two-fold. He also played an integral role in creating synergies between Ethicon and the Robotics and Digital Solutions teams to enhance integrations of technology platforms and utilization of product development best practices. Tezel joined Johnson & Johnson with broad experience in the medical technology industry including a strong history of driving innovation strategy, delivering new products to market as well as retaining and advancing key talent. He is a Credo-based leader who is dedicated to developing people and creating an inclusive work environment.
Tezel has held various executive positions in research, development, and tech transfer across a wide range of medical specialties and companies, including Alcon and Allergan. He earned a Ph.D. in chemical engineering from the University of California-Santa Barbara in transdermal drug delivery and vaccination, as well as a B.Sc., and M.Sc. in chemical engineering from Bogazici University in Istanbul, Turkey. Tezel and his family will continue to live in Summit, NJ.
Shen is retiring after working for Johnson & Johnson for more than 25 years.